The Fort Worth Press - Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

USD -
AED 3.672495
AFN 64.000314
ALL 82.253977
AMD 360.509431
ANG 1.790403
AOA 917.499428
ARS 1552.284702
AUD 1.48346
AWG 1.8025
AZN 1.697632
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778804
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.42811
CDF 2317.999791
CHF 0.838815
CLF 0.025259
CLP 994.110012
CNY 6.66455
CNH 6.665535
COP 3315.05
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.107101
DJF 177.720338
DKK 6.781775
DOP 60.559465
DZD 136.951012
EGP 53.7264
ERN 15
ETB 164.140883
EUR 0.90739
FJD 2.296803
FKP 0.758367
GBP 0.756145
GEL 2.594965
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.501804
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 332.705959
IDR 18268.2
ILS 3.254645
IMP 0.758367
INR 93.45945
IQD 1516.079284
IRR 1925253.999815
ISK 124.130485
JEP 0.758367
JMD 158.919789
JOD 0.709003
JPY 159.245985
KES 129.999866
KGS 87.448984
KHR 4080.072793
KMF 447.497229
KPW 900.00035
KRW 1334.25967
KWD 0.31158
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.861384
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.860197
MVR 15.410202
MWK 1734.212921
MXN 18.413075
MYR 4.093596
MZN 63.910227
NAD 16.918528
NGN 1348.670466
NIO 36.80602
NOK 9.59563
NPR 149.481136
NZD 1.81649
OMR 0.384501
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.585016
PKR 276.505202
PLN 3.993785
PYG 6230.864068
QAR 3.64562
RON 4.852297
RSD 106.739941
RUB 82.05711
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.825232
SDG 601.499925
SEK 10.096805
SGD 1.287735
SHP 0.758581
SLE 23.049694
SLL 20969.503664
SOS 571.501363
SRD 37.437951
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.77702
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.414697
TTD 6.771395
TWD 32.925901
TZS 2650.002957
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603599
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 595.208663
XAG 0.021073
XAU 0.000259007303
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 595.208663
XPF 108.509428
YER 236.503646
ZAR 16.92348
ZMK 9001.222553
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.06566
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.

Text size:

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.

Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. The investment, structured as a straightforward common stock transaction, was made at $7 per share representing a 20% premium to the closing price on the date of execution and included no warrants. The restricted shares further emphasize The Starwood Trust's confidence in the company's long-term strategy and potential.

This funding builds upon the $5 million non-dilutive line of credit extended by The Starwood Trust earlier this year, which remains undrawn. Together, these financial milestones reflect Telomir's commitment to advancing its innovative pipeline while aiming to maintain a strong financial foundation.

Recent Breakthroughs Highlight Telomir-1's Transformative Potential

Telomir recently announced potentially groundbreaking preclinical results for its lead compound, Telomir-1, confirming age-reversal and longevity benefits, as well as the ability to address Type 2 diabetes at its root cause. Studies showed significant reductions in fasting plasma glucose levels, improved glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.

Unlike current therapies that primarily manage symptoms, Telomir-1 addresses the root causes of aging and disease, including oxidative stress, chronic inflammation, telomere shortening, and regulation of metal overactivity, such as iron and copper dysregulation. This innovative approach positions Telomir-1 as a potential breakthrough therapy across multiple age-related conditions.

Erez Aminov, Chairman and CEO of Telomir, commented, "Securing funding at a premium to the closing price without warrants demonstrates the strength of our financial strategy and our commitment to delivering value to shareholders. These recent preclinical results reaffirm our belief in Telomir-1's ability to redefine how we treat chronic diseases and aging by addressing their root causes."

Expanding Research and Future Directions

Telomir is advancing its exploration in a pipeline of innovative therapies for critical conditions, including:

  • Progeria Studies: Investigating Telomir-1's effects on telomere stability and accelerated aging in human cell lines and nematode models.

  • Type 2 Diabetes: Further validating Telomir-1's ability to reverse insulin resistance and improve glucose homeostasis in rodent models.

  • Alzheimer's Disease: Assessing the molecule's role in mitigating neurodegeneration and cognitive decline.

  • Cancer Models: Evaluating applications in selective oncology conditions.

  • Wilson Disease: Targeting copper overload, a hallmark of this rare genetic disorder, through preclinical studies.

  • Osteoarthritis Models: Exploring Telomir-1's potential to improve joint health and mobility in age-related degenerative and inflammatory conditions.

The global market for age-reversal and age-related therapies offers significant opportunities, with a growing focus on therapies that address the underlying causes of these conditions. Telomir is poised to capitalize on these opportunities as it advances Telomir-1 toward clinical development.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, stated, "Telomir-1's potential extends far beyond treating symptoms-it targets the biological mechanisms underlying numerous chronic diseases. By addressing key drivers of cellular aging, inflammation and disease, such as oxidative stress, telomere shortening, and metal overload, Telomir-1 has the potential to fundamentally change the way we approach healthcare."

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of complex between DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the preclinical testing results described herein, (ii) anticipated timelines and subject matter for additional preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.

Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.

C.Rojas--TFWP